We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
-2.22%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$69.6M
Cap. Flow
% of AUM
6.48%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$12.7M |
| 2 |
Amazon
AMZN
|
+$9.6M |
| 3 |
Microsoft
MSFT
|
+$7.09M |
| 4 |
Analog Devices
ADI
|
+$4.96M |
| 5 |
Broadcom
AVGO
|
+$4.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Silver Trust
SLV
|
+$7.41M |
| 2 |
ProShares Ultra Gold
UGL
|
+$6.74M |
| 3 |
Arista Networks
ANET
|
+$6.7M |
| 4 |
Gilead Sciences
GILD
|
+$4.85M |
| 5 |
TSMC
TSM
|
+$4.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Pacira BioSciences
PCRX
$945M
| $231K | 0.02% |
9,282
-508
| -5% | -$12.2K |
|
302
Nike
NKE
$60.1B
| $229K | 0.02% |
3,559
-14,795
| -81% | -$1.09M |
|
303
Innoviva
INVA
$1.5B
| $228K | 0.02% |
12,572
-702
| -5% | -$12.6K |
|
304
Aurinia Pharmaceuticals
AUPH
$2.06B
| $221K | 0.02% |
27,548
-2,811
| -9% | -$22.8K |
|
305
Astera Labs
ALAB
$55.3B
| $221K | 0.02% |
3,700
-22,300
| -86% | -$2.06M |
|
306
Adaptive Biotechnologies
ADPT
$4.02B
| $220K | 0.02% |
29,602
-1,690
| -5% | -$13K |
|
307
Iovance Biotherapeutics
IOVA
$3.05B
| $219K | 0.02% |
65,766
+1,141
| +2% | +$5.88K |
|
308
Pulse Biosciences
PLSE
$3.09B
| $218K | 0.02% |
+13,551
| New | +$253K |
|
|
ETNB
309
DELISTED
89bio
ETNB
| $213K | 0.02% |
29,282
+4,350
| +17% | +$38K |
|
310
Syndax Pharmaceuticals
SNDX
$1.77B
| $210K | 0.02% |
17,121
-978
| -5% | -$13.8K |
|
311
Structure Therapeutics
GPCR
$3.83B
| $207K | 0.02% |
11,951
-683
| -5% | -$16.7K |
|
312
Novavax
NVAX
$1.31B
| $207K | 0.02% |
32,263
-1,702
| -5% | -$14.1K |
|
313
Geron
GERN
$1.01B
| $203K | 0.02% |
127,752
-424
| -0.3% | -$1.03K |
|
314
Spyre Therapeutics
SYRE
$9.18B
| $195K | 0.02% |
12,087
-353
| -3% | -$7.34K |
|
315
Enliven Therapeutics
ELVN
$4.24B
| $193K | 0.02% |
9,800
-560
| -5% | -$12.1K |
|
316
Harrow
HROW
$1.48B
| $190K | 0.02% |
7,144
-408
| -5% | -$12.2K |
|
317
10x Genomics
TXG
$7.52B
| $190K | 0.02% |
21,712
-975
| -4% | -$12.3K |
|
318
Collegium Pharmaceutical
COLL
$834M
| $189K | 0.02% |
6,315
-523
| -8% | -$16K |
|
319
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $187K | 0.02% |
8,426
-388
| -4% | -$7.99K |
|
320
Nurix Therapeutics
NRIX
$2.76B
| $181K | 0.02% |
15,222
+202
| +1% | +$3.38K |
|
321
Veeva Systems
VEEV
$39.2B
| $179K | 0.02% |
771
-5,400
| -88% | -$1.23M |
|
322
Vir Biotechnology
VIR
$1.52B
| $178K | 0.02% |
27,509
-1,693
| -6% | -$15.1K |
|
323
Autoliv
ALV
$8.85B
| $177K | 0.02% |
2,000
| – | – |
|
|
GRFS
324
Grifois
GRFS
$5.4B
| $174K | 0.02% |
24,470
-1,397
| -5% | -$10.5K |
|
|
GRAL
325
GRAIL Inc
GRAL
$3.08B
| $172K | 0.02% |
6,740
-385
| -5% | -$11.9K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q1 2025 Portfolio in Review
As of Q1 2025, China Universal Asset Management Company held 509 positions worth $1.07B, up 0.55% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
China Universal Asset Management Company deployed $69.6M of net new capital in Q1 2025, opening 13 new positions and adding to 172 existing holdings. Its largest new stake was VNET Group: 300,000 shares worth $2.46M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was iShares Silver Trust, an estimated $7.41M trimmed.
- China Universal Asset Management Company's largest Q1 2025 buy was VNET Group: 300,000 shares worth $2.46M.
- China Universal Asset Management Company added most to Apple in Q1 2025, an estimated $12.7M increase.
- China Universal Asset Management Company's biggest Q1 2025 reduction was iShares Silver Trust, cutting an estimated $7.41M.
- China Universal Asset Management Company fully exited Arista Networks in Q1 2025, selling an estimated $6.7M.
- China Universal Asset Management Company's ten largest holdings make up 36% of its $1.07B portfolio in Q1 2025.
- China Universal Asset Management Company opened 13 new positions and closed 23 in Q1 2025.
- China Universal Asset Management Company's portfolio value rose 0.55% quarter-over-quarter to $1.07B.
Based on China Universal Asset Management Company's 13F filing for Q1 2025, filed 30 Apr 2025.